ADHD Medication Choice Was Never About Which Works Better

Last updated: July 18, 2026

If your child takes stimulant medication for ADHD, or a doctor has suggested starting it, you have probably wondered whether the first prescription was the right pick. A yearlong randomized trial from the University of Sydney, one of the few head-to-head comparisons of the two leading stimulants over an extended period, found that dexamphetamine and methylphenidate improved children’s symptoms equally well. The difference showed up somewhere else: on the scale. Children taking dexamphetamine lost an average of 1.4 kilograms in the first three months, while children on methylphenidate lost about 300 grams and ended the year slightly heavier than they started. That moves the medication conversation away from “which drug is stronger” and toward a question parents are far better positioned to answer: which tradeoffs fit this particular child.

TL;DR

A University of Sydney randomized trial followed 100 stimulant-naive children with ADHD, aged 4 to 16, for 12 months.
Dexamphetamine and methylphenidate improved ADHD symptoms equally, with no significant difference in effectiveness.
Children on dexamphetamine lost an average 1.4 kg in the first three months versus about 300 grams on methylphenidate; at 12 months the dexamphetamine group averaged 0.84 kg below baseline while the methylphenidate group averaged 1.26 kg above.
Height growth showed no significant difference between the medications over the year.
The study was published July 17, 2026 in the Journal of Paediatrics and Child Health; lead author Dr Alison Poulton of the University of Sydney.

A yearlong randomized trial compared the two most commonly prescribed ADHD stimulants head to head and found no difference in symptom control. Here is what the trial showed, and the questions it hands parents.

Common questions

Which ADHD medication works better for children, dexamphetamine or methylphenidate?

In the first yearlong randomized head-to-head comparison, neither. Both improved attention, hyperactivity, and oppositional behavior equally in 100 children aged 4 to 16, and most children stayed on their original medication for the full 12 months. The meaningful difference was weight, not effectiveness.

Do ADHD stimulant medications affect a child’s growth?

In this trial, weight and height moved differently. Children on dexamphetamine lost an average of 1.4 kilograms in the first three months, while children on methylphenidate lost about 300 grams and finished the year above their starting weight. Height growth showed no significant difference between the medications over the 12 months studied. Regular weight and height checks, especially in the first three months, are the practical takeaway.

Should my child switch ADHD medication because of weight loss?

Never change a stimulant dose or medication without the prescriber involved. The study authors write that either medication is a reasonable first choice in specialist practice, with methylphenidate often preferred where weight loss is a particular concern. Bring food and growth observations to the appointment; because effectiveness was equal on average, a switch made for appetite or weight reasons does not mean trading away symptom control.

Is medication the only way to help a child with ADHD?

No. Medication addresses symptoms while it is active; focus, working memory, and self-regulation are skills that develop with structured practice, movement, and sleep, and the strongest results come from combining supports. Also worth knowing: a screener is a starting point, not a diagnosis. If your child might need formal accommodations through an IEP or 504 plan, or you suspect a vision, hearing, or medical cause, a professional evaluation is the route to those supports.

A yearlong head-to-head trial found the two leading ADHD stimulants control children's symptoms equally well. The real difference is weight. That changes the question parents should be asking. Tweet Now Follow Learning Success

What happened

Researchers at the University of Sydney and the Nepean Blue Mountains Local Health District ran an open-label randomized controlled trial with 100 children aged 4 to 16 who had been diagnosed with ADHD and had never taken stimulant medication. Each child was randomly assigned to dexamphetamine or methylphenidate and followed for 12 months, with the trial conducted between 2016 and 2020. The results were published July 17 in the Journal of Paediatrics and Child Health.

Both groups showed substantial improvement in attention, hyperactivity, and oppositional behavior, with no significant difference in effectiveness between the medications. Most children stayed on the treatment they started with; 62 of the original 100 were still on their assigned medication at the one-year mark. Height growth showed no significant difference between the two groups.

“Both medications worked equally well for improving ADHD symptoms, and most children remained on their original treatment over the first year,” said lead researcher Dr Alison Poulton, Senior Lecturer in Paediatrics and Child Health at the University of Sydney’s Nepean Clinical School. “The main difference was that children taking dexamphetamine experienced greater weight loss, which is an important consideration when choosing treatment and monitoring growth.”

Author Quote "

“Both medications worked equally well for improving ADHD symptoms, and most children remained on their original treatment over the first year. The main difference was that children taking dexamphetamine experienced greater weight loss, which is an important consideration when choosing treatment and monitoring growth,” said Dr Alison Poulton, Senior Lecturer in Paediatrics and Child Health, University of Sydney, the study’s lead researcher.

What the coverage gets wrong

Headlines like “One type of ADHD med may affect kids' weight” turn a tie into a warning label about a single drug. The randomized trial behind the headline found the opposite of a contest: both leading stimulants improved symptoms equally over a full year, height growth showed no significant difference in either group, and the weight gap is a manageable, monitorable factor rather than a reason for alarm. For a parent, this is decision data, not a scare. It means the choice rests on fit for your particular child, and your observations about appetite, growth, and daily follow-through are the evidence that should drive it.

The question the headlines get backwards

Much of the coverage frames this as a warning about one drug. A U.S. News headline reads “One type of ADHD med may affect kids’ weight.” That framing turns a tie into a scare story. The actual finding cuts the other way: with symptom control equal, potency stops being the deciding factor. What decides is fit: appetite, growth, sleep, and how a specific child responds. Those are exactly the things a parent observes across hundreds of dinners and bedtimes, while a prescriber sees a snapshot in a fifteen-minute visit.

The second correction matters even more. A pill that improves attention symptoms is a support for learning, not the learning itself. Attention, working memory, and self-regulation are skills that strengthen with the right kind of practice, and a well-chosen medication opens a window for that practice rather than replacing it. A diagnosis describes where your child is today. It does not predict where they’ll be in a year of the right kind of practice. Families who treat medication as one tool inside a broader plan to build focus and attention skills get more out of both.

This trial also retires a piece of waiting-room folklore: the idea that one stimulant is the strong one and the other the gentle one. Twelve months of randomized, head-to-head data found no difference in symptom control. The differences that remain are the ones families live with day to day, which is precisely why parents belong at the center of this decision.

Key Takeaways:

A genuine head-to-head: 100 children, randomized and followed 12 months; dexamphetamine and methylphenidate improved ADHD symptoms equally.

Weight is the real difference: dexamphetamine averaged 1.4 kg of loss in three months; methylphenidate about 300 grams.

The better question: with effectiveness tied, fit and growth monitoring should drive the choice, not assumed potency.

What this means for your child

If your child is starting or already taking a stimulant, this study hands you a short list of questions worth asking at the next appointment. What is the plan for tracking weight and height, especially during the first three months, when the dexamphetamine group lost the most? If eating drops off, what happens next: adjusted dose timing, breakfast before the morning dose settles in, calorie-dense snacks after school, or a medication change? The study authors write that either drug is a reasonable initial choice in specialist practice, with methylphenidate “preferred when weight loss is a particular concern.”

There is also reassurance here for families considering a switch. Because symptom control was equal on average, a child who struggles with appetite or weight on one stimulant is not condemned to choose between eating well and focusing well. A different medication, schedule, or dose stays on the table without giving up effectiveness, and that decision belongs with your prescriber and your own careful notes.

The forward-looking piece is the one no prescription covers: whichever medication your child takes, the skills still have to be built. Keep the movement, the sleep routine, and the daily focus practice running alongside the pill bottle, because that combination, not the brand name on the label, is what a year of progress is made of.

Parents get told the medication decision is technical and best left to the experts, and this trial says the opposite: once symptom control is equal, the deciding evidence is the kind only you collect, appetite at dinner, energy at practice, growth over months. The villain here is not either medication, it is the one-size horse-race framing that treats children as interchangeable and parents as spectators. Whichever prescription you and your doctor land on, the focus and self-regulation skills still have to be built, and Brain Bloom develops exactly those underlying skills so the window medication opens gets used: https://learningsuccess.ai/brain-bloom/?utm_source=blog&utm_medium=organic&utm_campaign=adhd-medication-choice-never-about-which-works-better&utm_content=kicker